Trials / Terminated
TerminatedNCT00679055
A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)
An Exploratory Double-Blind, Placebo Controlled, Randomized, 12-Week Oral Dose Study to Evaluate the Effects of MK0736 on Atherosclerotic Disease Biomarkers in Lower Extremity Plaque Excised From Patients With Peripheral Arterial Disease
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
A 12-Week Efficacy Study in participants with Peripheral Arterial Disease. the primary hypothesis is that MK-0736 7 mg administered once daily for 12 weeks will result in a decrease in lower extremity atherosclerotic plaque macrophage content when compared to placebo (an approximate decrease of up to 30% is expected).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-0736 | MK-0736; 7mg once daily, orally at approximately the same time each morning for 12 weeks. |
| DRUG | Comparator: placebo (unspecified) | Matching Placebo once daily, orally at approximately the same time each morning for 12 weeks. |
Timeline
- Start date
- 2007-03-31
- Primary completion
- 2008-08-26
- Completion
- 2008-08-26
- First posted
- 2008-05-16
- Last updated
- 2018-08-17
- Results posted
- 2015-02-16
Source: ClinicalTrials.gov record NCT00679055. Inclusion in this directory is not an endorsement.